亚临床冠状动脉粥样硬化:2013年ACC/AHA胆固醇管理指南他汀候选人群中冠状动脉CT血管成像表现的意义
本回顾性研究纳入4255例无症状自荐行冠状动脉CT血管成像(CCTA)者,中位随访87个月,按2013年ACC/AHA指南评估他汀推荐等级并分析主要不良心脏事件(MACE)。他汀推荐组中,CCTA示显著冠状动脉疾病(CAD)者MACE发生率显著高于非显著CAD者(p<0.001);在非显著CAD者中,使用他汀者无事件生存率显著更低(p=0.034)。在中强度他汀推荐患者中,CCTA节段累及评分与MACE风险显著相关(HR 2.558;p=0.001)。结论提示CCTA可能有助于无症状他汀候选人群的心血管疾病风险分层。
要点
- 他汀推荐组中,CCTA示显著CAD者MACE发生率显著高于非显著CAD者(p<0.001)。
- CCTA示冠状动脉正常者无论是否使用他汀均未发生MACE。
- 中强度他汀推荐患者中,CCTA节段累及评分与MACE风险显著相关(HR 2.558;p=0.001)。
核心结论
- CCTA可能有助于无症状他汀候选人群的心血管疾病风险分层。
研究设计与样本
- 回顾性研究,纳入4255例无症状且自荐行CCTA的个体,中位随访87个月;主要终点为主要不良心脏事件(MACE),包括心源性死亡、非致死性心肌梗死和不稳定型心绞痛;按2013年ACC/AHA指南推荐他汀者依评估风险进行分析。
诊断标准与关键数值
- 他汀推荐组中,CCTA示显著CAD者MACE发生率显著高于非显著CAD者(p<0.001)。
- CCTA示冠状动脉正常者无论是否使用他汀均未发生MACE。
- 他汀推荐组中,显著CAD者使用他汀与未使用他汀的MACE无显著差异(p=0.810)。
- 非显著CAD者中,使用他汀者的无事件生存率显著低于未使用他汀者(p=0.034)。
- 中强度他汀推荐患者中,CCTA节段累及评分与MACE风险显著相关(HR 2.558;p=0.001)。
临床应用与阅片要点
- 对按2013年ACC/AHA指南推荐他汀的无症状个体,可结合CCTA评估冠状动脉狭窄显著性与节段累及评分进行风险分层。
- CCTA示冠状动脉正常者随访中未发生MACE,提示该类人群事件风险低。
- 非显著CAD者中使用他汀者无事件生存率反而更低(p=0.034),解读该结果时需注意其观察性研究性质。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the cardiovascular outcome of statin medication in individuals retrospectively categorized on the basis of the 2013 American College of Cardiology and American Heart Association (ACC/AHA) guidelines risk assessment and to determine the additional prognostic value of coronary computed tomography angiography (CCTA) in assessing cardiovascular disease (CVD) risk in this group.
MATERIALS AND METHODS: This retrospective study reviewed 4255 asymptomatic individuals who had undergone self-referred CCTA with a median follow-up period of 87 months. The primary endpoint was major adverse cardiac events (MACEs); these included cardiac death, nonfatal myocardial infarction, and unstable angina. Individuals recommended for statins according to the ACC/AHA guidelines were analyzed by their assessed risk.
RESULTS: MACE occurrence was significantly higher in the statin-recommended (SR) group with significant coronary artery disease (CAD) than in those with insignificant CAD (p < 0.001). In individuals with a normal coronary artery on CCTA, MACEs did not occur regardless of statin medication. In the SR group with significant CAD, there was no significant difference between statin users and non-users (p = 0.810). However, in cases with insignificant CAD, the event-free survival was significantly lower among statin users (p = 0.034). In patients recommended for moderate-intensity statins, the segment involvement score on CCTA was significantly associated with a higher risk of MACEs (hazard ratio 2.558; p = 0.001).
CONCLUSION: CCTA might have a potential role in CVD risk stratification among asymptomatic statin candidates.
引用
- Seo J, Choi SI, Kim YK, et al. Subclinical Coronary Atherosclerosis: Implication of Coronary Computed Tomography Angiography Findings among Statin Candidates according to the 2013 ACC/AHA Cholesterol Management Guidelines. Korean J Radiol. 2019. PMID: 31270979. doi:10.3348/kjr.2018.0016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。